Correspondence

BCG transition to licensed vaccine letter

This letter is to advise that AJ Vaccines has resumed supply of the sole UK-licensed BCG vaccine to Public Health England’s central stockholding.

• From: Public Health England
• Published: 17 July 2018

This publication was withdrawn on 21 March 2022

This document has been withdrawn as it refers to vaccine supply in 2018. For the latest information, please visit BCG vaccination programme.

Documents

[Withdrawn] BCG transition to licensed vaccine letter

Ref: PHE publications gateway number: 2018255

PDF, 773 KB, 3 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

From June 2016, an alternative BCG vaccine from InterVax Ltd was supplied to enable the continuation of the programme. Alongside this PHE issued guidance and training materials to healthcare professionals on the administration of the vaccine, and information for parents and carers.

It is anticipated that PHE will be in a position to re-open ordering for the UK-licensed AJ Vaccines product in late July or August 2018. In the meantime, PHE will continue to make available InterVax BCG vaccine for ordering through the ImmForm website.

PHE anticipates having sufficient BCG vaccine for all eligible groups. Further information for healthcare workers on the use of the licenced vaccine will be available on the GOV.UK website.

Published 17 July 2018